Senti Biosciences Announces New Employment Inducement Grants
2024年12月4日 - 10:00AM
Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a
clinical-stage biotechnology company developing next-generation
cell and gene therapies using its proprietary Gene Circuit
platform, today announced that on November 26, 2024, the
Compensation Committee of Senti Bio’s Board of Directors granted to
three new employees stock options to purchase an aggregate of
49,778 shares of the Company’s common stock with a per share
exercise price of $2.11. These awards were made under the Company’s
2022 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the Company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The Plan was adopted by the
Company’s board of directors on August 5, 2022.
About Senti BioSenti Bio is a clinical-stage
biotechnology company developing a new generation of cell and gene
therapies for patients living with incurable diseases. To achieve
this, Senti Bio is leveraging a synthetic biology platform called
Gene Circuits to create therapies with enhanced precision and
control. These Gene Circuits are designed to precisely kill cancer
cells, spare healthy cells, increase specificity to target cells
and control the expression of drugs even after administration. The
Company’s wholly-owned pipeline includes off-the-shelf CAR-NK
cells, outfitted with Gene Circuits, to target challenging liquid
and solid tumor indications. Senti Bio has also preclinically
demonstrated that its Gene Circuits can function in T cells.
Additionally, Senti Bio has preclinically demonstrated the
potential breadth of Gene Circuits in other cell and gene therapy
modalities, diseases outside of oncology, and continues to advance
these capabilities through partnerships with Roche/Spark
Therapeutics and Bayer/Bluerock Therapeutics.
Availability of Other Information About Senti
BioFor more information, please visit the Senti Bio
website at https://www.sentibio.com or follow Senti Bio on X
(formerly Twitter) (@SentiBio) and LinkedIn (Senti Biosciences).
Investors and others should note that we communicate with our
investors and the public using our company website
(www.sentibio.com), including, but not limited to, company
disclosures, investor presentations and FAQs, Securities and
Exchange Commission filings, press releases, public conference call
transcripts and webcast transcripts, as well as on X and LinkedIn.
The information that we post on our website or on X or LinkedIn
could be deemed to be material information. As a result, we
encourage investors, the media and others interested to review the
information that we post there on a regular basis. The contents of
our website or social media shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended.
Senti Bio Contacts:
Investors: investors@sentibio.com
Media: media@sentibio.com
Senti Biosciences (NASDAQ:SNTI)
過去 株価チャート
から 11 2024 まで 12 2024
Senti Biosciences (NASDAQ:SNTI)
過去 株価チャート
から 12 2023 まで 12 2024